Replimune To Present Data From RP1 And RP2 Clinical Programs At The 2024 ASCO Annual Meeting; 12-Month Results From The IGNYTE Clinical Trial Of RP1 Plus Nivolumab In Anti-PD-1 Failed Melanoma Demonstrate An Overall Response Rate Of 32.7% And Duration Of Response Consistent With The Previously Reported 6-Month Data From IGNYTE Trial
Portfolio Pulse from Benzinga Newsdesk
Replimune Group, Inc. (NASDAQ: REPL) presented promising clinical data from its RP1 and RP2 programs at the 2024 ASCO Annual Meeting. The 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma showed an overall response rate of 32.7%. Additionally, RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrated an overall response rate of nearly 30%.
June 03, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Replimune Group, Inc. presented promising 12-month clinical data from its RP1 and RP2 programs at the 2024 ASCO Annual Meeting. The data showed significant response rates in melanoma treatments, which could positively impact the company's stock price.
The positive clinical data from the RP1 and RP2 programs, particularly the 32.7% response rate in anti-PD-1 failed melanoma, is likely to boost investor confidence and positively impact Replimune's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100